Literature DB >> 15131000

The complexities of the cardiovascular actions of cannabinoids.

Michael D Randall1, David A Kendall, Saoirse O'Sullivan.   

Abstract

The cardiovascular actions of cannbinoids are complex. In general they cause vasorelaxation in isolated blood vessels, while in anaesthetised animals they cause multiphasic responses which involve an early bradycardia and long-lasting hypotension. However, in conscious animals, the picture is one of bradycardia followed by pressor responses. Clearly, the responses to cannabinoids are dependent on the experimental conditions and synthetic cannabinoids and endocannabinoids exhibit different pharmacologies. In terms of mechanisms involved in the vascular responses to cannabinoids, the following have been implicated: the involvement of 'classical' cannabinoid receptors, the involvement of a novel endothelial cannabinoid receptor, the release of nitric oxide, the release of endothelium-derived hyperpolarising factor (EDHF), the activation of vanilloid receptors, metabolism of endocannabinoids to vasoactive molecules, and both peripheral inhibition and central excitation of the sympathetic nervous system.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15131000      PMCID: PMC1574918          DOI: 10.1038/sj.bjp.0705725

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  63 in total

1.  Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors.

Authors:  Z Járai; J A Wagner; K Varga; K D Lake; D R Compton; B R Martin; A M Zimmer; T I Bonner; N E Buckley; E Mezey; R K Razdan; A Zimmer; G Kunos
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-23       Impact factor: 11.205

2.  Cannabinoids. II. Cardiovascular effects.

Authors:  P Stark; P B Dews
Journal:  J Pharmacol Exp Ther       Date:  1980-07       Impact factor: 4.030

3.  The peripheral sympathetic nervous system is the major target of cannabinoids in eliciting cardiovascular depression.

Authors:  Nathalie Niederhoffer; Karin Schmid; Bela Szabo
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-04-23       Impact factor: 3.000

4.  The endothelial component of cannabinoid-induced relaxation in rabbit mesenteric artery depends on gap junctional communication.

Authors:  A T Chaytor; P E Martin; W H Evans; M D Randall; T M Griffith
Journal:  J Physiol       Date:  1999-10-15       Impact factor: 5.182

5.  Selective ligands and cellular effectors of a G protein-coupled endothelial cannabinoid receptor.

Authors:  László Offertáler; Fong-Ming Mo; Sándor Bátkai; Jie Liu; Malcolm Begg; Raj K Razdan; Billy R Martin; Richard D Bukoski; George Kunos
Journal:  Mol Pharmacol       Date:  2003-03       Impact factor: 4.436

Review 6.  Cannabinoid modulation of peripheral autonomic and sensory neurotransmission.

Authors:  Vera Ralevic
Journal:  Eur J Pharmacol       Date:  2003-07-04       Impact factor: 4.432

Review 7.  Cannabinoid pharmacology.

Authors:  W L Dewey
Journal:  Pharmacol Rev       Date:  1986-06       Impact factor: 25.468

8.  Endothelium-independent relaxation to cannabinoids in rat-isolated mesenteric artery and role of Ca2+ influx.

Authors:  W-S Vanessa Ho; C Robin Hiley
Journal:  Br J Pharmacol       Date:  2003-06       Impact factor: 8.739

9.  Characterisation of the vasorelaxant properties of the novel endocannabinoid N-arachidonoyl-dopamine (NADA).

Authors:  Saoirse E O'Sullivan; David A Kendall; Michael D Randall
Journal:  Br J Pharmacol       Date:  2004-02-09       Impact factor: 8.739

10.  Endocannabinoids protect the rat isolated heart against ischaemia.

Authors:  Philippe Lépicier; Jean-François Bouchard; Caroline Lagneux; Daniel Lamontagne
Journal:  Br J Pharmacol       Date:  2003-06       Impact factor: 8.739

View more
  52 in total

Review 1.  Triphasic blood pressure responses to cannabinoids: do we understand the mechanism?

Authors:  Barbara Malinowska; Marta Baranowska-Kuczko; Eberhard Schlicker
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

Review 2.  Endocannabinoids in cerebrovascular regulation.

Authors:  Zoltán Benyó; Éva Ruisanchez; Miriam Leszl-Ishiguro; Péter Sándor; Pál Pacher
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-01-29       Impact factor: 4.733

3.  Synergistic and additive interactions of the cannabinoid agonist CP55,940 with mu opioid receptor and alpha2-adrenoceptor agonists in acute pain models in mice.

Authors:  Shao M Tham; James A Angus; Elizabeth M Tudor; Christine E Wright
Journal:  Br J Pharmacol       Date:  2005-03       Impact factor: 8.739

4.  The cardiovascular actions of anandamide: more targets?

Authors:  Michael D Randall
Journal:  Br J Pharmacol       Date:  2005-07       Impact factor: 8.739

5.  Central and peripheral components of the pressor effect of anandamide in urethane-anaesthetized rats.

Authors:  Grzegorz Kwolek; Agnieszka Zakrzeska; Eberhard Schlicker; Manfred Göthert; Grzegorz Godlewski; Barbara Malinowska
Journal:  Br J Pharmacol       Date:  2005-07       Impact factor: 8.739

Review 6.  Endocannabinoids and the haematological system.

Authors:  M D Randall
Journal:  Br J Pharmacol       Date:  2007-08-20       Impact factor: 8.739

7.  In vivo effects of CB2 receptor-selective cannabinoids on the vasculature of normal and arthritic rat knee joints.

Authors:  J J McDougall; V Yu; J Thomson
Journal:  Br J Pharmacol       Date:  2007-11-05       Impact factor: 8.739

8.  The novel endocannabinoid receptor GPR18 is expressed in the rostral ventrolateral medulla and exerts tonic restraining influence on blood pressure.

Authors:  Anusha Penumarti; Abdel A Abdel-Rahman
Journal:  J Pharmacol Exp Ther       Date:  2014-01-15       Impact factor: 4.030

9.  Delta 9-tetrahydrocannabinol inhibits electrically-evoked CGRP release and capsaicin-sensitive sensory neurogenic vasodilatation in the rat mesenteric arterial bed.

Authors:  J D Wilkinson; D A Kendall; V Ralevic
Journal:  Br J Pharmacol       Date:  2007-09-10       Impact factor: 8.739

10.  Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/Spice: identification of novel cannabinoid receptor ligands.

Authors:  Krishna C Chimalakonda; Kathryn A Seely; Stacie M Bratton; Lisa K Brents; Cindy L Moran; Gregory W Endres; Laura P James; Paul F Hollenberg; Paul L Prather; Anna Radominska-Pandya; Jeffery H Moran
Journal:  Drug Metab Dispos       Date:  2012-08-17       Impact factor: 3.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.